Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 4/20 | 0.48 |
| ▸ | SI | P14410 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621332 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14747294 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL13756825 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL1296044 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL22251726 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL24872329 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL10236872 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14856334 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL7098842 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL12352431 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573717-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2018138684-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9572823-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20120289686-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8227188-B2 | Enhancement of influenza gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8168242-B2 | Situ fructooligosaccharide production and sucrose reduction | DANISCO US INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8115026-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110033859-A1 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-7767657-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2202239-A1 | RNAI inhibition of influenza virus replication | Alnylam Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100040728-A1 | Situ Fructooligosaccharide Production and Sucrose Reduction | GENENCOR INTERNATIONAL, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7626005-B2 | Inhibitors of aminoglycoside 6′-N-acetyltransferases, compositions and uses thereof | MCGILL UNIVERSITY (CA) | 2009-12-01 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040728-A1 | Situ Fructooligosaccharide Production and Sucrose Reduction | SI, MGAM, LCT | LGALS8 1136/4885L3MBTL1 4236/4885MAPT 1047/4885 |
| US-20100016250-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | TLR9, TLR1, TLR7 | LGALS8 1774/4885L3MBTL1 1537/4885MAPT 4471/4885 |
| US-20120289686-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LGALS8 1605/4885L3MBTL1 1024/4885MAPT 1768/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | LGALS8 229/4885L3MBTL1 572/4885MAPT 4669/4885 |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LGALS8 1605/4885L3MBTL1 1024/4885MAPT 1768/4885 |
| US-11021511-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, MAVS | LGALS8 3999/4885L3MBTL1 541/4885MAPT 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.